DS
NAMS icon

David Shaw’s NewAmsterdam Pharma NAMS Stock Holding History

David Shaw’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.09M Buy
+120,561
New +$3.97M ﹤0.01% 2578
2024
Q4 		– Sell
-18,345
Closed -$305K – 4710
2024
Q3 		$305K Buy
+18,345
New +$317K ﹤0.01% 3968

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

David Shaw's NAMS Position: Q2 2026 in Review

David Shaw opened a new position in NewAmsterdam Pharma (NAMS) in Q2 2026: 120,561 shares worth $4.09M. The stake represents ﹤0.01% of the portfolio and ranks #2578 among its holdings. This is a return to the name: David Shaw previously reported a position in NAMS as recently as Q3 2024.

David Shaw first reported a position in NAMS in Q3 2024 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • David Shaw held 120,561 shares of NewAmsterdam Pharma worth $4.09M as of Q2 2026.
  • NewAmsterdam Pharma was a new David Shaw position in Q2 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2578 holding.
  • David Shaw first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.